Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: AdCLD-CoV19 vaccine - Cellid; AdCLD-CoV19-1; AdCLDCoV19

Latest Information Update: 11 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellid Company
  • Class COVID-19 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II COVID 2019 infections

Most Recent Events

  • 21 Jun 2023 Cellid completes a phase I trial for COVID-19 infections (Prevention) in South Korea (NCT05047692)
  • 20 Jun 2023 Cellid in collaboration with International Vaccine Institute terminates a phase II trial in COVID-2019 infections (Prevention, In adults) (IM) based on the sponsor(manufacture)'s decision (NCT05520970)
  • 27 Mar 2023 Cellid completes a phase I/II trial in COVID-2019 infections (Prevention) in South Korea (IM, Injection) (NCT04666012)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top